The Federal Circuit on Friday reversed and vacated different portions of a Patent Trial and Appeal Board decision that upheld as invalid the asserted claims of a hospital bed patent, finding that the board erred in its logic and by not adequately explaining itself.
The U.S. Supreme Court's decision to overturn a California high court's ruling that 600 nonresidents could pursue claims against Bristol-Myers Squibb over a blood thinner drug heads this year's list of top product liability cases, along with a bankruptcy ruling exposing General Motors to millions of claims not related to its infamous ignition switch.
The dispute over the pain reliever Flanax continued in Virginia federal court Friday, with the two sides offering dueling arguments for summary judgment on Bayer AG's trademark claims and Belmora LLC's antitrust counterclaims.
A New York federal magistrate judge on Friday recommended confirming a $466,000 Russian arbitral award against a defunct Long Island pharmaceutical company that failed to appear in the arbitration and the current litigation, saying he found no reason not to do so.
A Pennsylvania man on Friday copped to his role in an insider trading conspiracy that profited from nonpublic tips about Celator Pharmaceuticals Inc.’s cancer drug and the company’s impending $1.5 billion sale, prosecutors said.
Mitsubishi Tanabe Pharma Corp. filed suit Friday in New Jersey federal court against India-based drugmaker Macleods Pharmaceuticals Ltd., alleging that the company had filed an abbreviated new drug application for a generic diabetes medication that would violate two of Mitsubishi’s patents.
A Pennsylvania appeals court on Friday rejected a bid by an artificial-knee product manufacturer and a marketing firm to further reduce a $16 million damages award to a patient who reinjured her knee during a promotional video for the product.
Efforts to use the sovereign immunity of Native American tribes to shield patents from America Invents Act reviews have roiled the patent world, but a new U.S. Supreme Court case could throw a wrench into the strategy. It would take a circuitous route to get there, but here’s a look at how it could happen.
Twitter brought us some of the smartest and wittiest observations about litigation and policy involving pharmaceuticals and food in 2017. Here, Law360 shares 17 tweets on news that left a lasting mark.
The Patent Trial and Appeal Board on Friday found a Hologic Inc. medical device patent was invalid and rejected a series of proposed substitute claims, following a recent Federal Circuit ruling many believed gave patent owners a better chance at amending patents in America Invents Act reviews.
A Delaware federal judge on Thursday refused a drug and medical device maker’s request to dismiss or transfer an infringement suit brought against it over three intravenous painkiller patents, greenlighting discovery to determine if the venue is indeed proper.
Republicans unveiled the final version of their tax cut bill on Friday that would impose a 21 percent flat rate on corporations, set the maximum individual tax rate at 37 percent and largely adopt the Senate’s proposal for pass-through businesses.
Over the last few weeks, Holland & Knight LLP, Epstein Becker Green, Quarles & Brady LLP and medical records startup Ciitizen have grown their health care and life sciences teams with pros from Laredo & Smith LLP, LifePoint Health and the U.S. Department of Health and Human Services.
Goodwin Procter LLP’s Stuart Cable was involved in several life sciences transactions over the last year, including guiding contract research organization Parexel International through a competitive and aggressive $5 billion acquisition process, earning him a spot as one of Law360’s 2017 Life Sciences MVPs.
The Trump administration closed a probe of Thailand’s intellectual property regime Friday following several steps the country took to improve its patent and trademark rules that had frustrated drugmakers and other companies for years.
The Pennsylvania judiciary logged another busy year in 2017 as members of both the appellate and trial benches handled major cases, including a wholesale reshaping of environmental law in the state and a string of eye-popping verdicts in pharmaceutical product liability cases.
A Brooklyn federal judge on Thursday refused to allow allegations of government misconduct to be heard by jurors in the fraud trial of former Katten Muchin attorney Evan Greebel, after revealing that a witness claims a prosecutor told him to change his story, drop his legal action against Retrophin Inc. and pay the pharmaceutical company $170,000.
New York’s highest court ruled Thursday in favor of two couples claiming they wouldn’t have had children through a fertility clinic had they known the egg donor was a genetic defect carrier, saying the statute of limitations began running at birth, rather than the date of the alleged medical malpractice.
The city of Greenfield, Massachusetts, became the latest municipality Thursday to accuse a slew of drug manufacturers and distributors including Purdue Pharma and Amerisourcebergen of deceptively marketing and illegally diverting prescription opioids, fueling a nationwide epidemic.
The Federal Circuit on Thursday averted potential chaos by not letting drugmakers use a wide variety of state laws to extract biosimilar manufacturing information from rivals, and its ruling will turn attention to what sort of information rivals must provide under federal law.
Federal courts across the country are handing down important rulings interpreting the U.S. Supreme Court’s landmark decision on False Claims Act liability in Universal Health Services v. Escobar. As the rulings keep pouring in, stay up to speed on Law360’s latest coverage and analysis of Escobar’s impact.
Bartlit Beck was a wonderful place to work for 18 years, and the lawyers there are not only excellent attorneys but also great people. That said, and stating my biases upfront, it is possible for me to look analytically at the Bartlit Beck fee model and make some observations on the pros and cons of one version of alternative fees, says J.B. Heaton, founder of investment analytics company Conjecture LLC.
It is irresponsible to fit the pharmaceutical industry into the mold of Big Tobacco. The opioid addiction crisis is a public health problem. Litigation is not a proper solution, say members of Kelley Drye and Warren LLP.
Practitioners should pay close attention to see whether indication-specific pricing is adopted for generic and biosimilar products. Though ISP is often proposed as a solution to rising health care costs, it is unclear whether it is compatible with the current legal frameworks in play, say Michael Cottler and Natasha Daughtrey of Goodwin Procter LLP.
We tell jurors how important they are to the successful implementation of our judicial system, but oftentimes we don’t treat them with the reverence they deserve. U.S. District Judge Amos Mazzant III of the Eastern District of Texas, Lisa Blue of Baron and Blue, and Robert Hirschhorn of Cathy E. Bennett & Associates advocate three jury system improvements that will give jurors an active voice and role in our civil and criminal jury trials.
U.S. Department of Justice prosecutors and law enforcement partners have secured more foreign bribery-related trial convictions and guilty pleas this year than in any other year in the history of the Foreign Corrupt Practices Act, in fact by almost twice as much. These are all significant cases with significant impacts, says Daniel Kahn, chief of the DOJ's FCPA Unit.
It used to be that hiring a good law firm was the single most important thing a company could do when facing litigation. You could now make the case that an organization’s most powerful asset in prosecuting or defending a claim is its information, says Linda Sharp, associate general counsel of ZL Technologies and chair of the ACC Information Governance Committee.
It's been an exciting year for the marijuana industry in Massachusetts, with cities and towns now determining whether to embrace the new economic development opportunities presented by recreational marijuana. However, investment in the industry remains risky because the cultivation, use, sale and possession of marijuana remains a crime under federal law, say William Moorman and John Ottaviani of Partridge Snow & Hahn LLP.
U.S. senators on both sides of the aisle have proposed cosmetic reform bills, making it likely that Congress will soon pass legislation regulating personal care products. This, in turn, is likely to result in greater litigation against companies making those products, say attorneys at Mintz Levin Cohn Ferris Glovsky and Popeo PC.
In its new report on the effects of automation in the workplace, McKinsey Global Institute identifies lawyers as less susceptible to the sort of automation that could put one-third of American workers out of a career by 2030. This may seem reassuring, but it doesn't mean automation won't disrupt our bottom line, says Michael Moradzadeh of Rimon PC.
Three recent False Claims Act settlements can teach health care organizations important lessons, such as how swiftly and transparently reacting to government inquiries can save a company's bottom line and the public's trust, says Garrett Mott of Hanson Bridgett LLP.